MiMedx Group, Inc (MDXG) – What Are Analysts Thinking About This Stock?

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have received an average rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $8.57.

A number of brokerages have recently commented on MDXG. Cantor Fitzgerald restated an “overweight” rating on shares of MiMedx Group in a research note on Tuesday, September 15th. Wall Street Zen raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Seaport Research Partners lowered MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Weiss Ratings upgraded MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, August 27th. Finally, Craig Hallum upped their target price on MiMedx Group from $6.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, August 27th.

MiMedx Group Stock Up 1.1%

NASDAQ:MDXG opened at $4.67 on Tuesday. The company has a market cap of $680.70 million, a PE ratio of 116.78 and a beta of 1.18. The company has a current ratio of 5.33, a quick ratio of 4.79 and a debt-to-equity ratio of 0.07. MiMedx Group has a twelve month low of $3.03 and a twelve month high of $7.97. The company’s 50 day moving average is $4.51 and its two-hundred day moving average is $4.06.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The firm had revenue of $64.36 million for the quarter, compared to the consensus estimate of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. Analysts anticipate that MiMedx Group will post -0.10 EPS for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors have recently made changes to their positions in MDXG. BlackRock Inc. purchased a new stake in MiMedx Group in the second quarter valued at approximately $46,795,000. Nantahala Capital Management LLC purchased a new position in MiMedx Group in the 2nd quarter valued at approximately $18,355,075. Paradigm Capital Management Inc. NY purchased a new position in MiMedx Group in the 2nd quarter valued at approximately $15,681,000. Renaissance Technologies LLC raised its stake in shares of MiMedx Group by 22.4% in the first quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company’s stock valued at $11,928,000 after acquiring an additional 552,806 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in MiMedx Group by 8.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,694,002 shares of the company’s stock valued at $10,640,000 after purchasing an additional 214,633 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc is a regenerative healthcare company that develops, manufactures and markets human placental tissue allografts and related biomaterial products. Its products are derived from donated human placental tissue and are processed for use in healthcare settings, including wound care, surgery and orthopedic applications.

The company’s portfolio includes tissue allografts such as EPIFIX, EPIEFFECT, GRAFIX and AMNIOFIX. These products are designed to support the management of chronic and acute wounds, surgical reconstruction and other clinical procedures.